References
- BauchauVDurhamSRPrevalence and rate of diagnosis of allergic rhinitis in EuropeEur Respir J200424575876415516669
- CanonicaGWPoulsenPBVestenbaekUCost-effectiveness of GRAZAX® for prevention of grass pollen induced rhinoconjunctivitis in Southern EuropeRespir Med200710191885189417611095
- BousquetJNeukirchFBousquetPJSeverity and impairment of allergic rhinitis in patients consulting in primary careJ Allergy Clin Immunol2006117115816216387600
- ValovirtaEMyrsethSEPalkonenSThe voice of the patients: allergic rhinitis is not a trivial diseaseCurr Opin Allergy Clin Immunol2008811918188010
- SchrammBEhlkenBSmalaAQuednauKBergerKNowakDCost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective studyEur Respir J200321111612212570119
- FratiFScuratiSDell-AlbaniIPuccinelliPIncorvaiaCPassalacquaGEvaluation of house dust mite allergy in real life: patients’ characteristics and satisfaction with treatmentEur Ann Allergy Clin Immunol2014461172124702868
- PetersenKDGyrd-HansenDDahlRHealth-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergyAllergol Immunopathol (Madr)200533629630216371215
- Centre NHSHouse dust mite allergen immunotherapy tablet (Mitizax) for house dust mite allergy-induced rhinitis and conjunctivitis – third line2013 Availabel from: http://www.hsric.nihr.ac.uk/topics/house-dust-mite-allergen-immunotherapy-tablet-mitizax-for-house-dust-mite-allergy-induced-rhinitis-and-conjunctivitis-third-line/Accessed November 17, 2016
- DemolyPEmmingerWRehmDBackerVTommerupLKleine-TebbeJEffective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized double-blind, placebo-controlled phase III trialJ Allergy Clin Immunol2016137244445126292778
- DurhamSREmmingerWKappASQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trialJ Allergy Clin Immunol20121293717725e522285278
- BurksACalderonMCasaleTUpdate on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus reportJ Allergy Clin Immunol201313151288129523498595
- BousquetJDemolyPMichelFBSpecific immunotherapy in rhinitis and asthmaAnn Allergy Asthma Immunol2001871 Suppl 1384211476474
- MarognaMSpadoliniIMassoloACanonicaGPassalacquaGLong-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective studyJ Allergy Clin Immunol2010126596997520934206
- LaekemanGSimoensSBuffelsJContinuous versus on-demand pharmacotherapy of allergic rhinitis: evidence and practiceRespir Med2010104561562520163944
- PooleCDBannisterCAAndreasenJNEstimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhino-conjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapyHealth Qual Life Outcomes2014129924927639
- PetersenKDKronborgCLarsenJNDahlRGyrd-HansenDPatient related outcomes in a real life prospective follow up study: Allergen immunotherapy increase quality of life and reduce sick daysWorld Allergy Organ J2013611524229439
- KlussmannJPSchädlichPKChenXRémyVAnnual cost of hospitalization, inpatient rehabilitation, and sick leave for head and neck cancers in GermanyClinicoecon Outcomes Res2013520321323717047
- AhlertMBreyerFSchwettmannLHow you ask is what you get: framing effects in willingness-to-pay for a QALYSoc Sci Med2016150404826730880
- NICEGuide to the Methods of Technology Appraisal2013 Available from: https://www.nice.org.uk/process/pmg9/chapter/forewordAccessed November 17, 2016
- IQWiGGeneral Methods for the Assessment of the Relation of Benefits to Costs 2009 Available from: https://www.iqwig.de/download/General_Methods_for_the_Assessment_of_the_Relation_of_Benefits_to_Costs.pdfAccessed June 24, 2016
- ZieglmayerPNolteHNelsonHSEvaluation of SQ-house dust mite sublingual immunotherapy tablet one-year after completion of a 24-week treatment periodJ Allergy Clin Immunol2016137Suppl 2AB62
- Heads of Medicines AgenciesACARIZAX – Summary of Product Characteristics Available from: http://mri.medagencies.org/Human/Product/Details/45380Accessed June 24, 2016
- McCarneyRWarnerJIIiffeeSvan HaselenRGriffinMFisherPThe Hawthorne effect: a randomised, controlled trialBMC Med Res Methodol200773017608932
- BachertCNoergaard AndreasenJCost-effectiveness of immunotherapy in the treatment of seasonal allergic rhinitis: identifying product-specific parameters of relevance for health care decision-makers and cliniciansInt Arch Allergy Immunol2015168321321726824384